Literature DB >> 7590876

Antagonistic peptides against human anaphylatoxin C5a.

Y Kaneko1, N Okada, L Baranyi, T Azuma, H Okada.   

Abstract

Multivalent synthetic peptides derived from C5a were prepared in order to examine their effects on the C5a receptor (C5aR). Multiple antigen peptide (MAP) of the C5a C-terminal region (MAP61-74) bound to cells expressing C5aR with high affinity. On the other hand, N-terminal peptides (MAP3-16 and MAP12-26) and one with a sequence from the mid-portion of C5a (MAP37-53) did not bind to the cells. In addition, MAP61-74 inhibited Ca2+ mobilization and release of beta-hexosaminidase by C5a from dibutyryl cAMP-activated U937 cells. This Ca2+ mobilization was also inhibited by MAP12-26 and Mono61-74, the monomeric C-terminal peptide. Taken together, these data indicate that C5a binds to the C5aR via its C-terminal region. Furthermore, MAP61-74, a 14mer peptide that has additional amino acids at the N-terminal compared with the C-terminal octapaptide, can bind to C5aR and can be considered an antagonist of C5a which may prove useful as an agent for controlling the allergic response caused by complement activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590876      PMCID: PMC1383823     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Biologic activity of synthetic analogues of C5a anaphylatoxin.

Authors:  J A Ember; S D Sanderson; S M Taylor; M Kawahara; T E Hugli
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

2.  C5a structural requirements for neutrophil receptor interaction.

Authors:  K W Mollison; T A Fey; R A Krause; L Miller; R P Edalji; R G Conway; W Mandecki; M A Shallcross; M Kawai; Y S Or
Journal:  Agents Actions Suppl       Date:  1991

3.  Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides.

Authors:  J Köhl; B Lübbers; A Klos; W Bautsch; M Casaretto
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

4.  The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs.

Authors:  J A DeMartino; G Van Riper; S J Siciliano; C J Molineaux; Z D Konteatis; H Rosen; M S Springer
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

5.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.

Authors:  S J Siciliano; T E Rollins; J DeMartino; Z Konteatis; L Malkowitz; G Van Riper; S Bondy; H Rosen; M S Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

6.  Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor.

Authors:  E L Morgan; J A Ember; S D Sanderson; W Scholz; R Buchner; R D Ye; T E Hugli
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

7.  Site-specific mutations in the N-terminal region of human C5a that affect interactions of C5a with the neutrophil C5a receptor.

Authors:  D F Carney; T E Hugli
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

8.  Generation of chimeric C5a/formyl peptide receptors: towards the identification of the human C5a receptor binding site.

Authors:  J E Pease; D R Burton; M D Barker
Journal:  Eur J Immunol       Date:  1994-01       Impact factor: 5.532

9.  Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain.

Authors:  M Oppermann; U Raedt; T Hebell; B Schmidt; B Zimmermann; O Götze
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

10.  Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.

Authors:  P Bubeck; J Grötzinger; M Winkler; J Köhl; A Wollmer; A Klos; W Bautsch
Journal:  Eur J Biochem       Date:  1994-02-01
View more
  2 in total

Review 1.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

2.  Identification of novel natural compound inhibitors for human complement component 5a receptor by homology modeling and virtual screening.

Authors:  Faraz Shaikh; Shirley W I Siu
Journal:  Med Chem Res       Date:  2016-05-05       Impact factor: 1.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.